Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682707 | 0.87 | NPC1 (0.45) | POLBHTTLMNAMEN1KMT2A | |
| SCHEMBL7427855 | 0.80 | ALDH1A1 (0.36) | POLBHTTLMNAKMT2AMAPT | |
| SCHEMBL682698 | 0.78 | GAA (0.38) | POLBHTTLMNAMEN1KMT2A | |
| SCHEMBL683508 | 0.77 | ALDH1A1 (0.39) | POLBHTTMEN1KMT2AMAPT | |
| SCHEMBL5848990 | 0.70 | ALDH1A1 (0.51) | POLBMEN1KMT2AMAPTKDM4E | |
| SCHEMBL6822071 | 0.67 | EGFR (0.46) | HTTMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL683860 | 0.67 | ALDH1A1 (0.37) | POLBLMNAKMT2AMAPTKDM4E | |
| SCHEMBL20620683 | 0.65 | HPGD (0.42) | POLBHTTLMNAMEN1KMT2A | |
| SCHEMBL269329 | 0.64 | LMNA (0.80) | POLBLMNAMEN1KMT2AMAPT | |
| SCHEMBL25150416 | 0.63 | HTT (0.50) | POLBHTTLMNAMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | POLB 1723/4885HTT 751/4885LMNA 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.